A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

Inclusion Criteria:

1. Aged ≥18 and <65 years at the time of signing the consent form

2. Subjects who had history of liver transplantation due to HBV-related end-stage liverdisease such as cirrhosis, liver cancer and fulminant hepatic failure and receivedtreatment for prevent hepatitis B recurrence

3. HBsAg(+) before liver transplantation

4. Subjects who have been received I.V.-Hepabig inj more than 3 times dose of 10,000International Unit/4weeks regimen

Exclusion Criteria:

1. Subject with history of anaphylaxis to any component of the investigational product

2. Pregnant or breast-feeding women

3. Deficiency of Immunoglobulin A

4. Clinically significant renal diseases (serum creatinine >2.0mg/dL, anuria, renalfailure or on dialysis at screening)

5. Hemophilia

6. Co-infection with Hepatitis A Virus, Hepatitis C Virus, or Human ImmunodeficiencyVirus

7. Subject with history of malignancy within the last 5 years (excluding primary livercancer)

8. Subject received estrogen or hormone replacement therapy within 3 months beforescreening

9. HBsAg or HBeAg or HBV DNA positive at screening

10. Anti HBs titer less than below criteria at screening <150 IU/L for subject whoseHBeAg and HBV DNA were negative(-) before liver transplantation >500 IU/L forsubject whose HBeAg or HBV DNA were positive(+) before liver transplantation

11. Subject with history of drug abuse

12. Participated in another clinical study within 30 days (relative to the last dose ofinvestigational product) before screening

13. Subject who are determined disqualified to join clinical trials by investigator